Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial.
Jonathan Ian SilverbergD TothThomas BieberA F AlexisBoni E ElewskiAndrew E PinkDirk-Jan HijnenT N JensenB BangC K OlsenAzra KurbasicStephan Weidingernull nullPublished in: The British journal of dermatology (2021)
Tralokinumab 300 mg in combination with TCS as needed was effective and well tolerated in patients with moderate-to-severe AD.